Advertisement
Advertisement
U.S. markets open in 6 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Monte Rosa Therapeutics, Inc. (GLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
4.7800-0.8400 (-14.95%)
At close: 04:00PM EDT
4.7100 -0.07 (-1.46%)
After hours: 04:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close5.6200
Open5.5800
Bid0.0000 x 1300
Ask0.0000 x 800
Day's Range4.7300 - 5.5800
52 Week Range4.4000 - 10.9600
Volume262,451
Avg. Volume148,253
Market Cap237.371M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-2.2700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GLUE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Monte Rosa Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MRT-2359 for the treatment of small cell lung cancer (SCLC)Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024Strong cash position expected to sustain operations into 2025 and enable advancement of p

  • GlobeNewswire

    Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

    BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. ”Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our B

  • Simply Wall St.

    We're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Advertisement
Advertisement